October 23, 2017 4:25 AM ET


Company Overview of BioQ Pharma Incorporated

Company Overview

BioQ Pharma Incorporated, a specialty pharmaceutical company, focuses on developing and commercializing a portfolio of ready-to-use infusible pharmaceuticals that includes products and product candidates for post-surgical pain and anesthesia, as well as development stage assets in sedation, antibiotics, and oncology. It offers Ropivacaine for post-operative pain management; Propofol for anesthesia and sedation; and pipeline spans antibiotics, sedation, and oncology pharmaceuticals. The company markets its pharmaceuticals through its commercial collaborators for U.S. market, EU market, and China, and Taiwan. It has strategic partnerships with Novartis’ Sandoz unit, Cipla, Lee’s Pharmaceutical...

185 Berry Street

Suite 160

San Francisco, CA 94107

United States





Key Executives for BioQ Pharma Incorporated

Chief Executive Officer and President
Chief Financial Officer
Age: 56
Compensation as of Fiscal Year 2017.

BioQ Pharma Incorporated Key Developments

STADA Pharmaceuticals Australia Pty Ltd. and BioQ Pharma Enter into Agreement

STADA Pharmaceuticals Australia Pty Ltd. and BioQ Pharma Inc. have entered into an agreement to commercialize three ready-to-use infusion pharmaceuticals in Australia and New Zealand. The three-product agreement between the partners includes Ropivacaine ReadyfusOR, an opioid sparing post-surgical pain management therapy, as well as two other product candidates. Ropivacaine ReadyfusOR is a ready-to-use, single use infusion product, which is pre-filled by the manufacturer with 0.2% Ropivacaine. Ropivacaine ReadyfusOR was recently approved by the Therapeutic Goods Administration (TGA). This agreement enables STADA Pharma and BioQ Pharma to introduce self-contained infusion pharmaceuticals to the Australian and New Zealand markets.

BioQ Pharma Incorporated Secures New Financing of Up to $55 Million from Madryn Asset Management, LP

BioQ Pharma Incorporated announced that it has secured new financing of up to $55 million from Madryn Asset Management, LP ('Madryn'). The proceeds of the investment will be used by BioQ to support product commercialization, scale-up manufacturing and operations, and continue new product development.

BioQ Pharma Incorporated Presents at UBS Global Healthcare Conference 2017, May-23-2017 02:00 PM

BioQ Pharma Incorporated Presents at UBS Global Healthcare Conference 2017, May-23-2017 02:00 PM. Venue: Grand Hyatt New York, 109 E 42nd St., New York , NY 10017, United States. Speakers: Joshua Kriesel, Chief Executive Officer and President, Ronald E. Pauli, Chief Financial Officer.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
August 15, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BioQ Pharma Incorporated, please visit bioquiddity.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.